NasdaqGS:EXELBiotechs
Exelixis (EXEL) Margin Expansion To 33.7% Tests Skeptical Growth Narratives
Exelixis (EXEL) has wrapped up FY 2025 with fourth quarter revenue of US$598.7 million and basic EPS of US$0.92, supported by trailing 12 month revenue of about US$2.3 billion and EPS of US$2.88 that sit alongside a higher net profit margin than a year ago. The company has seen quarterly revenue move from US$566.8 million and EPS of US$0.49 in Q4 2024 to US$598.7 million and US$0.92 in Q4 2025, while trailing net profit margin has stepped up from 24% to 33.7%. This sets up a story where...